Tengion Provides Clinical Update and Reports Third Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Tengion Provides Clinical Update and Reports Third Quarter 2014 Financial Results and Cash Position

WINSTON-SALEM, N.C., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported key clinical data along with financial and operating results for the quarter ended September 30, 2014.

"We remain committed to realizing the full value of our Organ Regeneration Platform and to maximizing value for our stakeholders and, therefore, in September, we announced that we retained Jefferies LLC as an executive financial advisor to assist us with reviewing and structuring potential strategic transactions," commented John L. Miclot, President and Chief Executive Officer of Tengion. "We look forward to providing further updates on this process as well as updates on our ongoing Phase 1 clinical trials for the Neo-Kidney Augment in Sweden and in the U.S. and potential next phase trials for the Neo-Urinary Conduit."

Neo-Kidney Augment™ (NKA) Cellular Therapy Clinical Update

Tengion is currently conducting Phase 1 clinical trials for its NKA cellular therapy in Sweden and the United States and, assuming the Company is able to obtain additional funding, expects to enroll up to 15 and 12 patients, respectively, in these two ongoing trials. Both Phase 1 trials are designed to evaluate the safety and delivery of an active regenerative dose of NKA cellular therapy, including two years of follow-up, in patients with chronic kidney disease (CKD). Assuming Tengion is able to obtain additional funding, the Company expects to report full data after completing patient enrollment for both trials during the first half of 2015.

In August 2014, Tengion announced encouraging six-month interim data for the first five patients with advanced CKD implanted in the Phase 1 clinical trial being conducted at the Karolinska Institute in Stockholm, Sweden. NKA cellular therapy was successfully implanted into one kidney of each patient. Tengion reported promising trends in the six-month data measurements of kidney function, including hemoglobin, serum creatinine, calculated estimated Glomerular Filtration Rate (eGFR), magnetic resonance imaging (MRI), and renal scintigraphy. Four surgical procedure-related serious adverse events were recorded in this trial. None of these events were determined to be related to the NKA material and none caused the patients to discontinue the trial or the Data Safety Monitoring Board to stop the trial. None of the reported adverse events were kidney-related.

Neo-Urinary Conduit™ Clinical Program Update

As of January 2014, Tengion completed enrollment in its ongoing Phase 1 clinical trial for the Neo-Urinary Conduit. Bladder cancer patients were enrolled in the trial to assess the safety and preliminary efficacy of the Neo-Urinary Conduit, as well as to translate the surgical implantation procedure utilized in preclinical studies. The Company is currently working with key opinion leaders on future development plans for the Neo-Urinary Conduit, and may seek to execute a strategic or financial transaction to provide targeted funding for future development of the Neo-Urinary Conduit. In the absence of such funding, the Company does not plan to continue independent development of the Neo-Urinary Conduit program.

Financial Results for the Three and Nine Months Ended September 30, 2014

For the three months ended September 30, 2014, the Company reported an adjusted net loss of $6.6 million, or $0.26 per basic and diluted common share, compared to an adjusted net loss of $6.0 million, or $1.40 per basic and diluted common share, for the same period in 2013. The increased adjusted net loss for the 2014 period was primarily due to an increase in research and development expense of $0.9 million, an increase in general and administrative expense of $0.1 million offset by a decrease in interest expense of $0.4 million.

For the nine months ended September 30, 2014, the Company reported an adjusted net loss of $19.3 million, or $0.96 per basic and diluted common share, compared with an adjusted net loss of $17.3 million, or $5.02 per basic and diluted common share, for the same period in 2013. The increased adjusted net loss for the 2014 period was primarily due to increases in research and development expense of $1.5 million, in general and administrative expense of $0.3 million and in interest expense of $0.2 million.

The increase in research and development expense for the three and nine months ended September 30, 2014 was primarily due to an increase in compensation and related expenses resulting from additional employees and an increased use of regulatory consultants, as well as an increase in external services related to the clinical trials for the Neo-Kidney Augment program. The increase in general and administrative expense for the three and nine months ended September 30, 2014 was primarily due to an increase in legal fees and professional services related to the preparation of a market assessment of the Neo-Kidney Augment program. The change in interest expense for the three and nine months ended September 30, 2014 was primarily due to non-cash interest expense associated with the Convertible Notes issued in the fourth quarter of 2012 and the second quarter of 2013.

As of September 30, 2014, the Company held $5.7 million in cash and cash equivalents. Based on the Company's current expected operating expenditures and debt repayment, and assuming it is not required to settle any outstanding warrants in cash or redeem, or pay cash interest on, any of its convertible notes, the Company expects to be able to fund its operations through mid-December 2014. Tengion is actively exploring opportunities to continue its business operations and fund deficits in operating cash flows. If Tengion is unable to raise additional capital, it will need to suspend its business operations and will likely need to seek protection under U.S. bankruptcy laws.

About the Neo-Kidney Augment™

The Neo-Kidney Augment is being developed to prevent or delay the need for dialysis by increasing renal function in patients with advanced chronic kidney disease. The Neo-Kidney Augment cellular therapy consists of selected regenerative renal cells obtained from a cortical biopsy of the patient's kidney, expanded ex vivo, and then formulated in a thermolabile gelatin for laparoscopic injection into the patient's kidney by a multi-ported needle, which allows the Neo-Kidney Augment cells to diffuse throughout the kidney and catalyze regeneration of functional kidney tissue.

About the Neo-Urinary Conduit™

The Neo-Urinary Conduit is designed to replace the standard of care for bladder cancer patients undergoing cystectomy (removal of bladder). There are over 25,000 cystectomies performed annually in bladder cancer patients in the United States and Europe. The Neo-Urinary Conduit is an implant made from a patient's own cells and is intended to catalyze regeneration of native-like urinary tissue, thereby eliminating the need to use bowel tissue in the current standard of care surgery.

About Tengion

Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. The Company is currently conducting Phase 1 clinical trials in Sweden and the United States for its Neo-Kidney Augment cellular therapy, which is intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease. A Phase 1 trial for the Company's Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal, has completed enrollment.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Tengion's plans, potential opportunities, or other expectations, projections, goals, objectives, strategies, timelines (including timelines regarding anticipated continued operations with current cash and cash equivalents), clinical studies, product development and the potential benefits of its products under development, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Tengion's operating performance, financial position, ability to raise additional funds on terms favorable to the company or at all, research, development and commercialization of products, the risks and uncertainties associated with meeting the objectives of its clinical studies, including, but not limited to, risks related to delays or failures resulting from slower than expected enrollment in clinical trials or clinical holds, and the occurrence of adverse safety events, obtaining regulatory approvals, risks related to Tengion's ability to complete any business development agreements on a timely basis or at all or on terms that are most beneficial for the company, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

TENGION, INC.
 
STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
         
         
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2014 2013 2014 2013
         
Revenue  $ --  $ --  $ --  $ --
         
Operating expenses:        
Research and development  $ 3,046  $ 2,169  $ 8,296  $ 6,829
General and administrative 1,603 1,520 5,165 4,815
Depreciation 55 59 157 204
Other expense, net 149 156 453 277
         
Total operating expenses  4,853  3,904  14,071  12,125
         
Loss from operations  (4,853)  (3,904)  (14,071)  (12,125)
         
Interest income  1  19  15  26
Interest expense  (1,859)  (2,246)  (5,704)  (5,503)
Change in fair value of embedded derivative and derivative liability  (2,856)  53  (6,631)  (4,385)
Change in fair value of warrant liability  (8,785)  (1,179)  (44,074)  (2,979)
         
Net loss  $ (18,352)  $ (7,257)  $ (70,465)  $ (24,966)
         
Basic and diluted net loss per share  $ (0.73)  $ (1.70)  $ (3.49)  $ (7.24)
         
Weighted-average common stock outstanding – basic and diluted  25,171  4,261  20,174  3,449
 
TENGION, INC.
     
BALANCE SHEET DATA
(in thousands)
(unaudited)
     
  September 30,
2014
December 31,
2013
Cash and cash equivalents  $ 5,728  $ 21,510
Total assets 9,621 25,724
Warrant liability 56,023 11,425
Total debt and embedded derivative, net of debt discount 33,326 26,952
Total liabilities 93,003 42,580
Total stockholders' deficit  (83,382)  (16,856)
 
TENGION, INC.
         
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(in thousands, except per share data)
(unaudited)
         
         
In accordance with Regulation G of the Securities and Exchange Commission, the table set forth below reconciles certain financial measures used in this press release that were not calculated in accordance with generally accepted accounting principles, or GAAP, with the most directly comparable financial measure calculated in accordance with GAAP.
         
         
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2014 2013 2014 2013
Net loss – GAAP  $ (18,352)  $ (7,257)  $ (70,465)  $ (24,966)
Change in fair value of embedded derivative and derivative liability 2,856  (53) 6,631 4,385
Change in fair value of warrant liability 8,785 1,179 44,074 2,979
Other expense, net 149 156 453 277
Adjusted net loss  $ (6,562)  $ (5,975)  $ (19,307)  $ (17,325)
         
Shares used in computing basic and diluted net loss attributable to common stockholders:        
Basic and diluted 25,171 4,261 20,174 3,449
         
Basic and diluted net loss per share - GAAP  $ (0.73)  $ (1.70)  $ (3.49)  $ (7.24)
Adjustment per share 0.47 0.30 2.53 2.22
Basic and diluted net loss per share - adjusted  $ (0.26)  $ (1.40)  $ (0.96)  $ (5.02)

Investor and Media Contact: A. Brian Davis 336.201.0155

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 145

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 41

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 46

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 91

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 95

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 125

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 117

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 73

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 22

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
/section>

Top 5 Most Recently Viewed Articles

Unveiling Groundbreaking Research on Cenobamate at AES 2025

Updated Category News Views 163

Exciting New Developments in Epilepsy Treatment SK Life Science, Inc., a leading player in central nervous system (CNS) disorder treatments and a subsidiary of SK Biopharmaceuticals Co., Ltd., is ready to unveil ten posters featuring new research on cenobamate at the upcoming American Epilepsy Society (AES) Annual Meeting. This prestigious event will take place in...

Continue Reading
Teck Resources Unveils Strong First Quarter Earnings for 2025

Updated Category News Views 384

Teck Resources Limited Reports Impressive First Quarter Results Teck Resources Limited (NYSE: TECK, TSX: TECK.A, TSX: TECK.B) has announced its unaudited financial results for the first quarter of 2025, showcasing significant improvements over previous years. This marks a period of enhanced profitability driven by favorable market conditions. Financial Performance...

Continue Reading
Understanding Your Rights in the Symbotic Class Action

Updated Category News Views 155

Taking Action: Your Rights as an Investor in Symbotic Inc. Investors of Symbotic Inc. should be aware of a class action lawsuit initiated on their behalf. The law firm Kirby McInerney LLP is advocating for those who acquired Symbotic securities during the noted class period. This comes as a crucial reminder for shareholders to stay informed and consider their rights in...

Continue Reading
Scott Kelly Joins Worthington Steel Board, Boosting Strategy

Updated Category News Views 431

Scott Kelly Named to Worthington Steel Board Worthington Steel, Inc. (NYSE:WS), a prominent player in the metals processing industry, has officially welcomed Scott Kelly to its board of directors. This strategic appointment comes at a significant time as the company navigates its market challenges, including a recent 10% dip in stock price. Despite this, Worthington...

Continue Reading
Treasury Securities Agreements: A New Era for Primary Dealers

Updated Category News Views 232

Understanding the Latest Developments in Treasury Securities In a significant move to fortify the issuance and market making in Treasury securities, the Government Debt Management, on behalf of the Treasury, has signed crucial agreements with primary dealers. This initiative aims to ensure the Treasury’s uninterrupted access to financing while enhancing price formation...

Continue Reading